# US 2026/0098260 A1 · Treating and preventing microbial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098260 A1
- Document ID: US20260098260A1
- Status: Published application
- Kind: A1
- Application number: 19/367,030
- Filed: 2025-10-23
- Published: 2026-04-09
- Earliest claimed: 2018-04-30
- Assignees: SNIPR Biome ApS
- Applicants: SNIPR Biome ApS
- Inventors: Morten SOMMER; Virginia MARTINEZ; Eric VAN DER HELM; Jakob Krause HAABER; Ana DE SANTIAGO TORIO; Christian GRØNDAHL; Jasper CLUBE
- Web page: https://patentgrep.com/patent/US20260098260A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 31/04: Antibacterial agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/30: Special therapeutic applications
- C12N 2320/31: Combination therapy
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

## Claims

### Claim at position 1

1: A method of reducing growth of a first Propionibacterium bacteria species or strain in a skin microbiota, the method comprising selectively modifying the first Propionibacterium bacteria species or strain comprised by the subject by cutting a target site comprised by the genomes of the first Propionibacterium bacteria species or strain,
wherein the method comprises administering to the subject a first nucleic acid sequence comprising a guide RNA or a DNA encoding the guide RNA,
wherein the cutting is carried out using a Cas nuclease that is programmed by the guide RNA to cut the target site,
wherein the subject comprises second bacteria of one or more strains or species that are different from that of the first Propionibacterium bacteria species or strain,
wherein the genomes of the second bacteria do not comprise the target site,
wherein the genomes of the second bacteria are not cut by the Cas nuclease in the subject, whereby second bacteria are not modified in the presence of the Cas nuclease in the subject, and
wherein the reduction of the growth of the first bacteria is maintained for at least 60 minutes after exposing the subject to the guide RNA.

### Claim at position 2 (depends on 1)

2: The method of claim 1, wherein the first nucleic acid sequence is a nucleic acid vector comprising the guide RNA or a DNA encoding the guide RNA.

### Claim at position 3 (depends on 1)

3: The method of claim 1, wherein the first nucleic acid sequence is administered in a vector that is a phage, phagemid, virophage, virus, plasmid, or transposon.

### Claim at position 4 (depends on 3)

4: The method of claim 3, wherein the vector is a phage or phagemid.

### Claim at position 5 (depends on 1)

5: The method of claim 1, wherein the method comprises topically administering to the subject the first nucleic acid.

### Claim at position 6 (depends on 1)

6: The method of claim 1, wherein the method comprises administering a pharmaceutical composition comprising the first nucleic acid sequence and a pharmaceutically acceptable diluent, carrier or excipient.

### Claim at position 7 (depends on 1)

7: The method of claim 1, comprising administering a second nucleic acid sequence to the subject, wherein the second nucleic acid sequence encodes the Cas nuclease.

### Claim at position 8 (depends on 7)

8: The method of claim 7, wherein the nucleic acid vector comprises both the first nucleic acid sequence and second nucleic acid sequence.

### Claim at position 9 (depends on 1)

9: The method of claim 1, wherein the Cas nuclease is a Cas9 or a Cas3.

### Claim at position 10 (depends on 9)

10: The method of claim 9, wherein the Cas nuclease is a Streptococcus pyogenes Cas9 (spCas9).

### Claim at position 11 (depends on 10)

11: The method of claim 10, wherein the second bacteria comprise a Staphylococcus, a Streptococcus, or a Corynebacterium bacteria.

### Claim at position 12 (depends on 1)

12: The method of claim 1, wherein the guide RNA is a single guide RNA.
